Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Times Interest Earned (2016 - 2025)

ImmunityBio (IBRX) has disclosed Times Interest Earned for 9 consecutive years, with -$4.36 as the latest value for Q4 2025.

  • On a quarterly basis, Times Interest Earned fell 63.19% to -$4.36 in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.21, a 39.97% decrease, with the full-year FY2025 number at -$4.21, down 40.0% from a year prior.
  • Times Interest Earned was -$4.36 for Q4 2025 at ImmunityBio, down from -$3.65 in the prior quarter.
  • In the past five years, Times Interest Earned ranged from a high of $4.55 in Q4 2022 to a low of -$27.23 in Q1 2021.
  • A 5-year average of -$7.56 and a median of -$3.97 in 2025 define the central range for Times Interest Earned.
  • Peak YoY movement for Times Interest Earned: surged 125.78% in 2022, then tumbled 159.04% in 2023.
  • ImmunityBio's Times Interest Earned stood at -$17.66 in 2021, then soared by 125.78% to $4.55 in 2022, then crashed by 159.04% to -$2.69 in 2023, then rose by 0.62% to -$2.67 in 2024, then crashed by 63.19% to -$4.36 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Times Interest Earned are -$4.36 (Q4 2025), -$3.65 (Q3 2025), and -$4.61 (Q2 2025).